Vaxcyte CEO Grant Pickering Makes Insider Purchase

Grant Pickering, the Chief Executive Officer of Vaxcyte, Inc. (NasdaqGS: PCVX), purchased 225 shares of the company on June 18, 2026. The shares were bought at an average price of $1.79 each, marking a total transaction value of $402.75. This insider activity highlights Pickering's interest in the company's stock.

Insider Buying and Selling at Vaxcyte, Inc.

Grant Pickering, CEO of Vaxcyte, made a significant insider purchase by acquiring 225 shares at $1.79 each on June 18, 2026. Additionally, Andrew Guggenhime, the President and CFO, was involved in multiple transactions on the same day, buying 10,000 shares at $5.35 and selling 10,000 shares at $53.00 under a planned sale.

Other Institutional Activity in Vaxcyte

Several institutional investors have been active in Vaxcyte. Janus Henderson Group PLC increased its holdings by 3,188,687 shares, bringing its total to 16,575,875 shares valued at approximately $960.2 million. FMR LLC also boosted its stake by 2,658,347 shares, ending with 16,492,861 shares worth about $958.4 million. T. Rowe Price Investment Management, Inc. added 829,684 shares to hold 12,126,017 shares valued at $704.6 million. RA Capital Management, L.P. and BlackRock, Inc. both increased their positions as well, with RA Capital adding 750,000 shares and BlackRock adding 725,438 shares.

Vaxcyte, Inc. Stock Down 14.2%

Shares of Vaxcyte, Inc. are currently trading at $50.67. The company has a market capitalization of approximately $7.32 billion. Vaxcyte's forward P/E ratio is not meaningful due to its current lack of profitability. The stock has a 52-week range between $29.08 and $65.00, with a 50-day moving average of $53.89 and a 200-day moving average of $48.95. The company's beta is 1.242, indicating a moderate level of market volatility.

Analysts Set New Price Targets

Analysts have been active in evaluating Vaxcyte's stock. On February 26, 2026, BTIG maintained its 'buy' rating with a price target of $89. Guggenheim reiterated its 'buy' rating with a $116 target on February 2, 2026. Needham also maintained its 'buy' rating, setting a target of $110 on January 7, 2026. Overall, the consensus among nine analysts is a 'strong buy' with a mean price target of $109.

About Vaxcyte

Vaxcyte, Inc. is a clinical-stage biotechnology company based in San Carlos, California. It focuses on developing conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. The company's lead product is VAX-24, a vaccine candidate aimed at preventing invasive pneumococcal disease. Vaxcyte also works on other vaccine candidates, including VAX-31 and VAX-A1, targeting various infectious diseases. The company, formerly known as SutroVax, Inc., was founded in 2013 and employs around 507 people.

Bottom Line

The recent insider purchase by Vaxcyte's CEO, Grant Pickering, is a noteworthy development for investors tracking insider activity. Vaxcyte's stock is currently trading at $50.67, with a substantial market cap, though it remains unprofitable. Analysts maintain a positive outlook with a 'strong buy' consensus and a mean price target of $109. As always, it's important to remember that insider transactions are reported after the fact and may not reflect current positions.